$17.03
近くで: Sep 25, 5:00 PM EST
$17.04
0.0140.08%
時間外: Sep 23, 5:58 PM EST
Benzinga
Benzinga
Benzinga
土曜日, 9 26
Theravance Biopharma Inc
TBPHNASDAQ
M&A: Theravance Biopharma (TBPH) was acquired by Zymeworks (ZYME) on Wednesday, September 23, 2026 for $929M paid in cash
Theravance Biopharma Earnings & Forecasts
Theravance Biopharma (TBPH) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Theravance Biopharma Guidance
Recent Earnings Results
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $0.08 | $0.06 | $0.34 | $-0.08 |
| Actual | $0.18 | $-0.10 | $1.15 | $0.07 |
| Surprise | +125.0% | -266.7% | +238.2% | +187.5% |
| Revenue | ||||
| Estimate | $21.8M | $17.5M | $54.3M | $19.8M |
| Actual | $20.7M | $17.7M | $45.9M | $20.0M |
| Surprise | -4.98% | +0.86% | -15.6% | +1.12% |
Analyst Estimates — Forward PeriodsSource: Wall Street consensus
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $0.20 | $0.20 | $-0.09 | $-0.02 |
| Revenue | ||||
| Consensus | $20.7M | $24.1M | — | — |
Earnings & Guidance News
Benzinga
© 2026 Benzinga | All Rights Reserved